ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.909,14
-0,25%
S&P 500
5.881,63
-0,43%
Dow Jones
42.544,22
-0,07%
Euro vs US Dollar
1,03498
0,00%
Bitcoin
93.766,49
0,41%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Cytokinetics Inc (CYTK) Börsenkurse

Cytokinetics Inc

Cytokinetics Inc (CYTK)

NASDAQ
47,04
-0,11
(-0,23%)
Geschlossen 01 Januar 10:00PM
Verzögert um 15 Minuten
47,04
0,04
(0,09%)
Nach Börsenschluss: 1:19AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
47,04
Gebot
46,40
Fragen
50,51
Volumen
798.176
46,80 Tagesbereich 47,78
45,66 52-Wochen-Bereich 110,25
Marktkapitalisierung
5,551B
Handelsende
47,15
Handelsbeginn
47,50
Letzte Trade
95
@
46.99
Letzter Handelszeitpunkt
Finanzvolumen
US$ 37.686.233
VWAP
47,2154
Durchschnittliches Volumen (3 Mio.)
1.164.105
Ausgegebene Aktien
118.014.240
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-10,54
Gewinn pro Aktie (EPS)
-4,46
Erlöse
7,53M
Nettogewinn
-526,24M

Über Cytokinetics Inc

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, ... Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.cytokinetics.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Cytokinetics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYTK. The last closing price for Cytokinetics was US$47,15. Over the last year, Cytokinetics shares have traded in a share price range of US$ 45,66 to US$ 110,25.

Cytokinetics currently has 118.014.240 shares in issue. The market capitalisation of Cytokinetics is US$5,56 billion. Cytokinetics has a price to earnings ratio (PE ratio) of -10.54.

Option-Flow Cytokinetics (CYTK)

Vollständigen Option-Flow anzeigen

Gesamtfluss

Bullisch

Nettoprämie

193k

Calls / Puts

300,00%

Käuf. / Verkä.

0,00%

OTM / ITM

100,00%

Sweeps

0,00%

CYTK Neueste Nachrichten

Weitere Nachrichten

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing...

23 Dezember 2024
GlobeNewswire Inc.

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize...

20 Dezember 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

17 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

16 Dezember 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Dezember 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

10 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

05 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

05 Dezember 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.81-3.7052200614148.8549.1146.5279973747.75588469CS
4-3.31-6.5739821251250.3551.9845.66112298648.88358341CS
12-8.405-15.159166741855.44559.3945.66116410551.74609023CS
26-6.88-12.759643916953.9261.3845.66120682853.90941383CS
52-37.34-44.252192462784.38110.2545.66195565566.59467672CS
1561.623.5667107001345.42110.2525.98146741552.78324828CS
26036.79358.92682926810.25110.258131681442.81904739CS

CYTK - Frequently Asked Questions (FAQ)

What is the current Cytokinetics share price?
The current share price of Cytokinetics is US$ 47,04
How many Cytokinetics shares are in issue?
Cytokinetics has 118.014.240 shares in issue
What is the market cap of Cytokinetics?
The market capitalisation of Cytokinetics is USD 5,56B
What is the 1 year trading range for Cytokinetics share price?
Cytokinetics has traded in the range of US$ 45,66 to US$ 110,25 during the past year
What is the PE ratio of Cytokinetics?
The price to earnings ratio of Cytokinetics is -10,54
What is the cash to sales ratio of Cytokinetics?
The cash to sales ratio of Cytokinetics is 736,68
What is the reporting currency for Cytokinetics?
Cytokinetics reports financial results in USD
What is the latest annual turnover for Cytokinetics?
The latest annual turnover of Cytokinetics is USD 7,53M
What is the latest annual profit for Cytokinetics?
The latest annual profit of Cytokinetics is USD -526,24M
What is the registered address of Cytokinetics?
The registered address for Cytokinetics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Cytokinetics website address?
The website address for Cytokinetics is www.cytokinetics.com
Which industry sector does Cytokinetics operate in?
Cytokinetics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BDMDBaird Medical Investment Holdings Ltd
US$ 7,6699
(630,47%)
89,74M
APMAptorum Group Ltd
US$ 2,799
(106,57%)
116,74M
COEPCoeptis Therapeutics Holdings Inc
US$ 5,44
(75,48%)
5,08M
VRMEVerifyMe Inc
US$ 1,332
(68,63%)
94,03M
VEEETwin Vee PowerCats Company
US$ 0,55
(53,59%)
5,62M
WATTEnergous Corporation
US$ 1,00
(-62,26%)
29,33M
SGMOSangamo Therapeutics Inc
US$ 1,02
(-56,41%)
44,55M
INTZIntrusion Inc
US$ 3,07
(-45,95%)
15,07M
KZIAKazia Therapeutics Ltd
US$ 1,78
(-42,58%)
708,99k
TOIIWOncology Institute Inc
US$ 0,0052
(-42,22%)
366,02k
SVMHSRIVARU Holding Ltd
US$ 0,0423
(26,65%)
794,59M
XTIAXTI Aerospace Inc
US$ 0,0422
(6,84%)
446,2M
EYENEyenovia Inc
US$ 0,1474
(30,10%)
412,81M
CRKNCrown Electrokinetics Corporation
US$ 0,146899
(5,91%)
402,04M
ONCOOnconetix Inc
US$ 0,6479
(48,26%)
270,46M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
CYTK
Cytokinetics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten